Skip to main content
PharmGen Science, Inc. logo

PharmGen Science, Inc. — Investor Relations & Filings

Ticker · 004720 ISIN · KR7004720009 KO Manufacturing
Open in API
Filings indexed 296 across all filing types
Latest filing 2024-03-20 AGM Information
Country KR South Korea
Listing KO 004720

About PharmGen Science, Inc.

http://www.pharmgenscience.com/en/

PharmGen Science, Inc. is a pharmaceutical company engaged in the research, development, production, and sale of medicaments. The company's portfolio encompasses a range of prescription (ETC) and over-the-counter (OTC) drugs, including analgesics, antibiotics, and anti-inflammatory agents. A key strategic focus for the company is the discovery and development of novel drugs for gastrointestinal (GI) disorders. PharmGen Science aims to provide integrated pharmaceutical solutions by leveraging its diverse infrastructure and global network.

Recent filings

Filing Released Lang Actions
[기재정정]주주총회소집공고
AGM Information Classification · 98% confidence The document is a 'Notice of General Meeting of Shareholders' (주주총회소집공고) which includes detailed financial statements (balance sheets, income statements, cash flow statements) as part of the meeting agenda materials. According to the 'Menu vs Meal' rule, while it contains financial data, the primary purpose of this document is to provide shareholders with the necessary information and agenda for the upcoming Annual General Meeting. Therefore, it is classified as a Proxy Solicitation & Information Statement (PSI).
2024-03-20 Korean
[기재정정]의결권대리행사권유참고서류
Proxy Solicitation & Information Statement Classification · 100% confidence The document is titled '의결권대리행사권유참고서류' (Reference Document for Solicitation of Proxy), which is a standard Korean regulatory filing (Proxy Solicitation) used to provide shareholders with information regarding upcoming general meetings, including agenda items and financial summaries. It is not an Annual Report (10-K) or an Earnings Release (ER), but rather a formal proxy statement (PSI) required for shareholder voting procedures.
2024-03-20 Korean
주주총회소집공고
AGM Information Classification · 98% confidence The document is a 'Notice of General Meeting of Shareholders' (주주총회소집공고) for PharmGen Science. It contains the agenda for the 58th Annual General Meeting, including voting items such as the approval of financial statements, director remuneration, and auditor remuneration. It also includes management information, business outlook, and preliminary financial statements. This type of document is standard for proxy solicitation and shareholder meeting materials, which falls under the 'Proxy Solicitation & Information Statement' category.
2024-03-13 Korean
의결권대리행사권유참고서류
Proxy Solicitation & Information Statement Classification · 100% confidence The document is titled '의결권대리행사권유참고서류' (Reference Document for Solicitation of Proxy), which is a standard regulatory filing in Korea (Proxy Solicitation & Information Statement) used to request shareholder votes for an upcoming Annual General Meeting. It contains details on the meeting agenda, voting procedures, and management information. While it includes financial data, it is primarily a proxy solicitation document rather than an Annual Report or Earnings Release.
2024-03-13 Korean
주주총회소집결의
AGM Information Classification · 98% confidence The document is a formal notice of a General Meeting of Shareholders (주주총회소집결의) for PharmGen Science. It outlines the date, location, and agenda items (such as financial statement approval and director compensation). This type of document is a standard proxy solicitation or notice of meeting, which falls under the Proxy Solicitation & Information Statement category.
2024-03-11 Korean
매출액또는손익구조30%(대규모법인은15%)이상변경
Earnings Release Classification · 100% confidence The document is a regulatory filing from PharmGen Science regarding a change in financial structure (revenue/profit/loss) of 30% or more. This is a standard preliminary earnings announcement (often referred to as a 'preliminary results' or 'earnings release' in the context of Korean regulatory filings) that provides key financial highlights before the final audited report is published. It fits the definition of an Earnings Release (ER) as it provides initial financial performance data. FY 2023
2024-02-14 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.